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Abstract
Background: Inappropriate medication and polypharmacy increase morbidity, hospitalisation rate, costs and mortality
in multimorbid patients. At hospital discharge of elderly patients, polypharmacy is often even more pronounced than
at admission. However, the optimal discharge strategy in view of sustained medication appropriateness remains
unclear. In particular, unreflectingly switching back to the pre-hospitalisation medication must be avoided. Therefore,
both the patients and the follow-up physicians should be involved in the discharge process. In this study, we aim to
test whether a brief medication review which takes the patients’ priorities into account, combined with a standardised
communication strategy at hospital discharge, leads to sustained medication appropriateness and extends readmission
times among elderly multimorbid patients.
Methods: The study is designed as a two-armed, double-blinded, cluster-randomised trial, involving 42 senior hospital
physicians (HPs) with their junior HPs and 2100 multimorbid patients aged 60 years or older.
Using a randomised minimisation strategy, senior HPs will be assigned to either intervention or control group.
Following instructions of the study team, the senior HPs in the intervention group will teach their junior HPs
how to integrate a simple medication review tool combined with a defined communication strategy into their ward’s
discharge procedure. The untrained HPs in the control group will provide data on usual care, and their patients will be
discharged following usual local routines.
Primary outcome is the time until readmission within 6 months after discharge, and secondary outcomes cover
readmission rates, number of emergency and GP visits, classes and numbers of drugs prescribed, proportions of
potentially inappropriate medications, and the patients’ quality of life after discharge. Additionally, the characteristics of
both the HPs as well as the patients will be collected before the intervention. Process evaluation outcomes will be
assessed parallel to the ongoing core study using qualitative research methods.
Discussion: So far, interventions to reduce polypharmacy are still scarce at the crucial interface between HPs and GPs. To
our knowledge, this trial is the first to analyse the combination of a brief deprescribing intervention with a standardised
communication strategy at hospital discharge and in the early post-discharge period.
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Background
Polypharmacy, particularly among multimorbid older
patients, is associated with increased risks of adverse
drug reactions and interactions, prescription and intake
errors and low patient adherence [1–3], resulting in
higher morbidity, hospitalisation rates, costs and mortal-
ity in affected patients [4–6]. Along with rising levels of
mulitmorbidity, the prevalence of and therefore the
importance to manage polypharmacy have significantly
increased over the last years [7], and related recommen-
dations and guidelines have emerged [8, 9].
Hospitalisation is strongly associated with polyphar-
macy, with the number of drugs at discharge being
considerably higher than at the time of admission [10].
Furthermore, a high number of drugs at hospital dis-
charge has been shown to be, independent of relevant
comorbidities and cognitive status, a predictor for early
readmission in older patients [11]. Nonetheless, inter-
ventions to reduce polypharmacy—which exist in
variable grades of complexity, feasibility and dissemin-
ation—have so far mainly been adopted by specialists
like geriatricians or pharmacologists but are not widely
used at the crucial interface between hospital physicians
(HPs) and general practitioners (GPs) [12–18].
This is surprising given that suitable discharge inter-
ventions have the potential to considerably reduce re-
admission rates and extend readmission times: studies
have shown reductions of 30-day readmission rates be-
tween 15% and 50% [19, 20], and a recent systematic
Cochrane review demonstrated a relative risk reduction
of 13% (RR 0.87; 95% CI 0.79–97) for readmission after
planned discharge interventions [21]. Time to readmis-
sion could be extended by one third (from 12 to 18 days)
in a frail population of older adults (≥ 60 years) by a
transitional care program [22].
However, in order to persistently reduce polypharmacy
among discharged patients, it is not sufficient to optimise
medication plans at discharge. Unreflectively switching
back to pre-hospitalisation medication schemes has been
identified as a common pitfall to be avoided for a sus-
tained effect [23]. Consensus between the hospital and
follow-up physicians with regard to the discharge medica-
tion leads to higher adoption rates of the medication plans
in the post-discharge period, compared to unidirectional
communication [24]. Therefore, it is of utmost importance
to involve both the patients and their GPs in the prescrib-
ing/deprescribing decisions at discharge [25].
None of the studies mentioned above—and to our
knowledge no other trial either—analysed the effects of
a discharge strategy which incorporates both crucial
aspects of deprescribing and collaborative communica-
tion between HP and GP at hospital discharge. This
paper describes the protocol for a randomised controlled
study designed to fill this gap.
Trial objectives
The aim of this study is to investigate the benefits of re-
ducing polypharmacy among discharged multimorbid
hospital patients by means of an improved discharge
procedure combining a brief deprescribing intervention
and a standardised communication strategy. In particu-
lar, we aim at analysing the impact of the new procedure
on readmission rates and times, the number of drugs as
well as the proportion of potentially inappropriate
medications (PIMs) at discharge, and on the discharged
patients’ quality of life (QoL) within a 6 month
follow-up.
Secondary objectives are to explore determinants of
the new procedure’s implementation into the daily
routine and to estimate potential cost savings, in order
to build the empirical basis for its future dissemination
as a “best practice” model among Swiss hospital wards
and GPs.
Study hypothesis
We hypothesise that a simple medication review tool
in combination with a defined communication strat-
egy at hospital discharge (intervention group) extends
time to hospital readmission compared to usual care
(control group) and improves the patients’ health out-
comes and QoL in the post-discharge period.
Methods/design
Study design and setting
The core trial has been designed as a prospective,
double-blind, bi-centre, cluster-randomised parallel-
controlled study with 4 months of patient recruitment
per cluster and individual follow-ups of 6 months and
will be accompanied by a process evaluation study
(see Fig. 1 for the study flow chart).
Study population
Patients in hospitals of all types, levels and legal struc-
tures in northern, eastern and central Switzerland are
eligible and can participate if they fulfil all the following
inclusion criteria:
 In-hospital patient at the time of inclusion
 Male or female of 60 years or older with five or
more drugs prescribed
 Signed informed consent or—in case of a patient
incapable of judgement—consent from a legal
representative according to Swiss law (HRA Art. 24,
1a.-c. and SCC Art. 378)
The prescription of five or more drugs (a commonly
used definition of polypharmacy [26]) is used as a
proxy for multimorbidity, and patients with cognitive
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impairment are included as well in order to increase
generalisability of the results.
The following exclusion criteria will apply:
 End-stage disease with a life expectancy of less than
3 months
 Cognitive inability to follow study procedures
neither independently nor with assistance
 Secondary exclusion: patient is transferred to
another ward or another hospital
Hospitals which took part in the Swiss national pilot
project “progress! Sichere Medikation an Schnittstellen”
[27] will not be considered for participation in the study
because the said project involved a medication review
which might confound our intervention effect.
Recruitment and allocation
Eligible hospitals will be contacted on the medical
management level with detailed written information
about the study and an invitation to participate. Each
consenting senior HP from a participating hospital,
together with his ward’s junior HPs and their patients,
will constitute a cluster. Choosing disjoint clusters will
minimise the possibility of contamination within the
same hospital ward.
Sufficiently large blocks of clusters [28] will be
allocated to the study arms using covariate-constrained
Fig. 1 Study flow chart with accompanying process and impact evaluation. Coloured rectangles provide data for the impact evaluation (IE), and
rounded edges indicate stages of the process evaluation (PE1-10). Numbers refer to the items in Additional file 1. SC, study centre; HD, hospital
director; HP, hospital physician; GP, general practitioner
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randomisation [29], i.e. by randomly choosing (by an in-
dependent third party) from a set of randomly generated
allocation schemes with sufficient balance in terms of
hospital types (acute-care vs rehabilitation, rural vs cen-
tral, academic vs non-academic) as well as type (medical
discipline) and size (number of beds) of hospital wards.
In-hospital recruitment of patients will be performed
by HPs or nurses; a person responsible for recruitment
will be defined in every ward. Patients will be recruited
during 4 months or until the targeted number of 50 par-
ticipants per cluster is reached.
Blinding
Blinding of HPs in its strictest sense is not possible
within the chosen study design. In order to achieve a
certain degree of blinding, the HPs will be informed that
the study aims at investigating the effects of different
discharge strategies on readmission times but they will
not be offered detailed information about the other
study arm. This will prevent the discharging HPs and
their patients from knowing which of the two arms they
were allocated to.
Intervention
The intervention will take place on different levels with
different target populations:
A. Cluster level: “Teach-the-Teachers” session for the senior
HPs in charge of postgraduate training and supervision of
the junior HPs
The purpose of this training of 2 h duration is to teach
and motivate HPs to integrate a specific discharge pro-
cedure (Table 1) into the daily work of the HPs. The
teaching session will address the following items:
 How to identify eligible patients according to the
in- and exclusion criteria
 How to apply a simple medication review tool to the
patients’ medication list
 How to involve the senior HPs in the medication
reviews
 How to identify the patients’ needs and priorities
 How to involve the patient in active shared decision
making about his/her treatment
 How to create revised discharge medication plans
for the patients
 How to involve the GPs in the post-discharge period
 How to deal with the different data collection forms
Following their own training, the senior HPs will
instruct the junior HPs how to apply the structured dis-
charge procedure to their patients. The senior HPs will
also be responsible for the instruction of junior HPs who
get newly assigned to their wards as part of the junior
HPs’ job rotations. This approach guarantees consistency
of the intervention even where fluctuation among junior
HPs is high.
B. Patient level: The intervention at discharge
The junior HPs will perform critical reviews of their pa-
tients’ medication lists, supervised by their senior HPs,
discuss the results of these reviews and their suggestions
with the patients and create optimised discharge medica-
tion plans to be used by the patients. To ensure correct
and complete implementation of the discharge proced-
ure, the junior HPs will document these steps by ticking
answer boxes on the specific checklist (Table 1). The pa-
tients will be encouraged, by written and direct verbal
information, to consult their GPs within 7 days of being
discharged.
Depending on features and flexibility of the hospital
information system and its electronic record features,
Table 1 Checklist for the discharging hospital physician
Yes No
1: Have you collected the main complaint of
the patient?
□ □
2: Have you and your patient discussed the
treatment goals from his own point of view?
□ □
3: Have you compiled a full list of all the
patient’s drugs at admission?
□ □
4: Have you decided for every single drug
whether
▪ the patient will indeed take it as prescribed? □ □
▪ the indication of the drug is correct for this
patient?
□ □
▪ the risk of side effects (present or expected)
is less than the benefit incurred?
□ □
▪ the dose is correct for this individual patient
(age, comorbidities)?
□ □
▪ there is no alternative drug with a better
benefit-to-risk ratio?
□ □
5: Have you decided whether a new drug is
indicated?
□ □
6: Did you involve the patient in the changes you
are proposing?
□ □
7: Have you provided the patient with a discharge
medication list together with an invitation to
use it?
□ □
8: Have you motivated the patient to consult the
family doctor/general practitioner within 7 days?
□ □
9: Did you send the list of modified or newly
introduced medications to the family doctor/
general practitioner?
□ □
10: Was there any contact with the general
practitioner during the hospital stay in view
of the imminent discharge of the patient?
□ □
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the junior HPs will communicate either the final revised
medication lists or listings of all medication changes
(cessation of specific medication, change of dosage,
introduction of new drugs) to the patients’ GPs in writ-
ten form. Furthermore, these notifications will be ac-
companied by invitations to the GPs to discuss the
medication changes.
In the control arm, the senior HPs will undergo a 2 h
educative session addressing multimorbidity, the need
for epidemiological and outcome data for this specific
population, patient in- and exclusion criteria and the
handling of the different data collection forms. All pa-
tients in the control group will be discharged according
to the usual local routines.
Implementation
The implementation of the discharge strategy under study
can be understood as a two-step process as illustrated in
our model in Fig. 2. Step 1 represents the experimental im-
plementation of the intervention as a cluster RCT, covering
the intervention process itself as well as the short-term im-
pact of the intervention, while step 2 constitutes the imple-
mentation of the intervention in practice, comprising
maintenance and dissemination (long-term impact).
Outcome measures
The primary and secondary outcome measures will be
collected on the individual patient level from hospital
records or from the patients themselves (patient records
or questionnaires).
A. Primary outcome
Number of days until the first readmission to (any)
hospital within 6 months after discharge.
B. Secondary outcomes
 Readmission rates at 1, 3, and 6 months after discharge
 Number of emergency department (ED) visits or GP
encounters within 1, 3 and 6 months after discharge
 Death during follow-up of 6 months
 If applicable: reasons for readmission, ED visits, GP
encounters or death
 Number of drugs at discharge and at 1, 3, and
6 months after discharge
 Anatomical Therapeutic Chemical (ATC) classes of
the drugs prescribed/deprescribed at discharge and
at 1, 3, and 6 months after discharge
 Proportion of potentially inappropriate medications
(PIMs) based on 2012 Beers criteria [30] and the
PRISCUS list [13] at discharge and at 1, 3, and
6 months after discharge
 Patients’ quality of life on the EQ-5D-3L-scale [31] at
discharge and at 1, 3, and 6 months after discharge
The following covariates will be collected at the time
of inclusion of clusters or individuals, respectively, and
Fig. 2 Framework model for process (dark grey) and impact evaluation (light grey), adapted from Grant et al. [32]. Bold frames indicate
extensions to the original framework; asterisks mark thematic focus. cRCT, cluster RCT; HP, hospital physician; GP, general practitioner
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used for balanced cluster allocation and subgroup
analyses:
 Patient characteristics (age, sex)
 Hospital type (acute-care, rehabilitation, rural,
central, academic, non-academic)
 Type (medical discipline) and size (number of beds)
of hospital wards
C. Process and additional impact outcomes
At several stages of the ongoing RCT, additional process
and impact outcomes will be collected from all relevant
stakeholders (Fig. 1 and Additional file 1). The evalu-
ation will follow an adapted form of the framework pro-
posed by Grant et al. [32] (Fig. 2).
In its original form, the framework has been developed
for two-levelled cluster RCTs of complex interventions,
addressing clusters (in the present study: senior HPs)
and individuals (here: patients). In order to account for
the hierarchical structure of our study, we added two
additional levels to the framework (marked with orange
frames in Fig. 2) representing the institutions (hospitals)
and direct providers (junior HPs), respectively, thus
resulting in a four-dimensional model of the interven-
tion process (Fig. 2).
Additional file 1 contains a comprehensive list of items
addressed within the process and impact evaluation
study, with mappings to their respective framework ele-
ments, target groups and study stages.
a. Process The process evaluation will cover the recruit-
ment of the institutions as well as recruitment, interven-
tion delivery and response with regard to all other
cluster hierarchy levels. Generally, we will describe the
implementation together with facilitating strategies as
carried out but also characteristics, exposure and the ex-
periences of the target groups, as suggested in [33–35].
Thereby, we intend to identify mechanisms that poten-
tially act on primary and secondary outcomes and to ex-
plore factors affecting the implementation process
including implementation fidelity [36]. Accordingly, we
will focus (indicated by * in Fig. 2) on the recruitment of
hospitals and health professionals, including the descrip-
tion of their characteristics, as well as on their response
and the actual intervention delivery to the patients.
b. Impact Short-term: The assessment of the effective-
ness of the intervention on the patient-level, i.e. the ef-
fects on primary and secondary outcomes [32], is part of
the core RCT and has been described above. Addition-
ally, we will record unintended consequences of the
intervention, meaning “change in other outcomes which
may be perverse, harmful or beneficial” [32].
Long-term: Since—in case of positive outcomes—we
intend to assess and promote long-term maintenance of
the intervention in recruited hospitals after completion
of the trial, and to foster potential distribution to further
hospitals, we included the assessment of the long-term
impact of the intervention subsequent to the cluster
RCT in our framework model.
c. Empirical background and context In addition to
the cluster structure of the trial, the framework we
adapted for process and impact evaluation also con-
siders the empirical basis underlying the development
of the intervention as well as the context in which the
trial is being conducted, the latter also with regard to
assessing the generalisability of the study results.
Evaluating the effectiveness of the intervention will
allow inference on the empirical background (see the
Background section above) and its adequacy for the
study design. Context factors to be studied include
characteristics of the hospitals (spectrum of medical
services offered, diversity and flexibility of patient
information systems, financial and other resources
available for innovation and research, etc.) and of the
follow-up GPs and their communication with the dis-
charging HPs (eg. perception of the communication
offers, frequency of communication, reasons to con-
tact the discharging HPs).
d. Operationalisation The list in Additional file 1
operationalises the concept outlined above. For ex-
ample, ratings of feasibility and acceptance of the
intervention will be collected in order to assess its
relevance from both senior and junior HPs (by items
16 and 25) using 5-point Likert scales (Additional file 2).
Barriers to and enablers of deprescribing will be
explored among senior HPs in telephone interviews
(item 18) following a qualitative method approach with
both Likert items and open-ended questions (Add-
itional file 3). Context factors pertaining to the hospi-
tals and hospital directors will be collected in item 6,
and in order to measure the adequacy of the commu-
nication triggers, item 27 will capture HP-GP contacts
during inpatient stays with regard to the impending
discharge, as well as the frequency of the GPs’ utilisa-
tion of communication offers from HPs.
e. Ethics For ethical reasons, the control group hospital
directors and HPs will get full access to the intervention
(training for the deprescribing intervention at discharge)
after completing the study. Consecutively, their process
outcome measures will be explored as well, similar to
the intervention group exploration as described above.
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Follow-up
One, 3, and 6 months after discharge, the patients will
be contacted in writing by the study centre and asked to
report any readmissions, ED visits and GP encounters
(with reasons, if applicable) since discharge in paper case
report forms (CRFs). The patients will also be asked to
submit their current medication plans and short QoL
questionnaires to the study centre. In case of outstand-
ing responses, the study team will contact patients, rela-
tives, GPs, and/or hospitals by phone or in written form
in order to complete the missing data.
Data collection procedures
The senior HPs will document the participation of
each patient in an enrolment log to be kept at their
hospitals. The study centre will keep a file of CRFs
for each study participant with all relevant data per-
taining to the participant during the study. The forms
will be encoded, and the codes will be stored at the
hospitals. Decoding will be possible if case-tracking is
needed (in case of adverse events). For coding, data
and query management, monitoring and reporting
purposes, the current version of the clinical data
management tool “OpenClinica” (OpenClinica, LLC)
will be used. The transfer from paper to electronic
data will be carried out and independently double-
checked by different research associates.
Sample size calculation
We modelled hospital readmission time by fitting an ex-
ponential survival curve on published readmission rates
[20, 22] and internal data from the University Hospital
Zurich. Extending readmission time by 25% [20] was
considered a relevant effect of the intervention. In the
fitted model, this translates into an increase of the me-
dian readmission time by 23.2 days (from 92.7 days to
116.8 days) and corresponds to a hazard ratio of 0.80 be-
tween intervention and control group participants. This
is equivalent to a decrease of 18.2% in readmission rates
after 30 days (from 20.1% to 16.4%).
Based on this hazard ratio and assuming a two-sided
α = 5%, a power of 1-β = 80%, an intraclass correlation
coefficient (ICC) of 0.02 as in [37], 40% overall censoring
probability and equally sized clusters of 50 patients, we
calculated a sample size of 21 clusters and 1050 individ-
uals per trial arm. Thus, 42 senior HPs and 2100
patients in total will need to be included in order to
observe a relevant effect of the study intervention with
sufficient power.
Plan of statistical analyses
Descriptive statistical methods will be used to describe
the study population, including dropouts and losses to
follow-up. Baseline characteristics of both intervention
and control group will be calculated with corresponding
95% confidence intervals where applicable. In particular,
baseline variability among different hospitals will be
assessed by retrospectively analysing the discharge pre-
scriptions of all includable patients in the last month
prior to the start of patient recruitment.
The primary outcome will be compared between groups
using Kaplan-Meier estimators and log-rank tests. To
compare factors which may affect readmission, the Cox
proportional hazards model will be used considering clus-
tering by senior HPs as a random factor. The multivariable
model will include patient characteristics as well as all
covariates used for balanced allocation, and subgroup ana-
lyses may be carried out for such factors or covariates.
An interim analysis is planned once 50% of the partici-
pants have been recruited.
For secondary outcomes, parametric (t test) or
non-parametric tests (χ2 and Wilcoxon tests) will be
used as appropriate. Determinants associated with a
change of the medication will be investigated by explora-
tory, multivariate regression analysis.
The analyses of primary and secondary outcomes
will follow the intention-to-treat principle. Missing
values will be replaced by standard multiple imput-
ation (MI) as recommended by Ma et al. [38] for
clustered designs with variance inflation factors < 3.
Per-protocol analyses will be performed within the
scope of sensitivity analyses.
As a secondary analysis using the original data, a cost
analysis will be carried out on the basis of present medi-
cation prizes, and costs saved by spared drugs and
avoided hospitalisations will be estimated.
For process evaluation purposes, a qualitative methods
approach will be adopted to analyse data from question-
naires and interviews (either face to face or by phone).
Ratings of feasibility and acceptance of the intervention
(Additional file 2) and quantitative data gained from the
exploration of barriers and enablers of deprescribing
(Additional file 3) will be summarised and presented
using descriptive statistics and graphical methods. For
the interviews with study staff, a focus group of hospital
directors, senior HPs and with a random subset of GPs,
semi-structured interview guides will be used with room
for open-ended comments (an example is given in Add-
itional file 3.) The structured part of the interview will
cover key areas compiled from the relevant literature
[39–45] by consensus among the study team, while the
open part will be evaluated using quantitative content
analysis methodology [46, 47]. In a first inductive step,
the answers will be searched for codes not fitting into
the predefined key areas. New key areas will be defined
accordingly, again by consensus, until saturation is
reached. In the second step, all open-ended answers will
be coded using the refined list of key topics.
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Timeframe
The study will start with a short pilot test phase to check
the study tools in late 2018. Searching for participating
hospitals and recruitment of senior HPs will take place be-
tween mid- and end of 2018, and inclusion of the first
patients is planned for early 2019. For more details about
the study schedule, see the SPIRIT diagram (Fig. 3):
Patient safety and monitoring
The study is considered to entail only minimal risks and
burdens for the medical personnel and patients involved
since the intervention consists of education and—on the
patient level—critical reviews and potential optimisations
of discharge medication plans by trained physicians with
the possibility to immediately reverse any change in case
of unintended side effects. Therefore, and because the
retrospective collection of safety outcomes (readmissions,
ED visits, GP encounters, deaths) forms an integral part of
the study design, no dedicated safety board will be estab-
lished. Possible causal dependencies of serious adverse
events on the study intervention will be assessed by the
study team and reported to the responsible ethics commit-
tee. Insurance is covered by the University Hospital
Zurich’s open policy for clinical and non-clinical trials.
The study centre will collaborate with the Clinical
Trials Center (CTC) of the University Hospital Zurich to
ensure monitoring. All original data including the pa-
tient files (in particular all written informed consents
and the CRFs) will be subject for monitoring. Monitor-
ing will be performed primarily by phone and—if
needed—by visits at the project sites.
Confidentiality and data security
The patient names and all other confidential informa-
tion fall under medical confidentiality rules and will be
treated according to applicable Swiss data security laws.
For contact maintenance and case tracking (e.g. in case
of adverse events), the patients’ identities will be known
to a study nurse not involved in the analysis of the pa-
tient data. The patients’ names will not be accessible to
the scientific study staff. All electronic data, including
interview transcripts, will be stored under password
protection on secure network drives of the University
Hospital Zurich.
Discussion
Study rationale
Several recently published protocols describe trials
which aim at examining the effects of individual medica-
tion reviews taking the patients’ views on medication
appropriateness and treatment priorities into account
[48, 49]. Our study pursues similar goals but is unique
with respect to, firstly, the setting at hospital discharge
as a crucial interface between HPs and GPs, and
secondly, the addition of a communication strategy to
the medication review. By inviting the follow-up GPs to
discuss the prescribing/deprescribing decisions, we hope
to achieve a better consensus between HPs, GPs, and pa-
tients on their medication plans, and thus a lower rate
of switching back to prior medication lists and a higher
rate of patient adherence to their medication plans.
Strengths and limitations
Strengths of this study include its focus on the interface
between hospital medicine and primary care, its flexible
set-up regarding pre-existing in-hospital structures and
the investigation of both the intervention tool itself as
well as its implementation.
The transition from hospital back to home is a delicate
but crucial step on the patients’ paths to resume their
usual lives. To our knowledge, the study intervention is
unique in its objective to structure and organise this
step, not only by providing a set of instructions regard-
ing optimal discharge medication but–beyond that–by
implementing communication enablers between all ac-
tors involved.
The study design is flexible in so far as in order to
minimise the additional workload of the participating
HPs, optimal data collection and transmission proce-
dures at discharge will be worked out individually and
cooperatively with each hospital or hospital ward.
The accompanying process and implementation evalu-
ation will contribute to a better explanation of the inter-
vention effects and provide valuable information needed
for potential optimisation of the discharge strategy under
study and later propagation and dissemination in larger
settings.
A possible limitation might be that the contamination
between clusters within the same hospital cannot be
fully excluded. Varying degrees of protocol adherence by
the discharging HPs in the intervention arm and consid-
erable inhomogeneity among the discharge routines
followed by different hospitals in the control arm of the
study might partly obscure the intervention effect.
Conclusion
The results of the present study will enlarge the
knowledge base about optimal discharge procedures
of elderly multimorbid patients. If successful and well
received, the intervention under study has the poten-
tial to propel the development of better discharge
routines and may fuel initiatives to reduce polyphar-
macy and its associated adverse effects among dis-
charged patients. Ultimately, the study could lead to
both cost reductions in the health care system and
gains in quality of life for patients.
From the process assessment and implementation re-
sults, we expect to learn whether our approach will be
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Fig. 3 Study schedule (SPIRIT diagram of trial stages of enrolment, intervention, outcome assessment and evaluation). R, Recruitment; T, Training;
A, Admission; D, Discharge; T1/3/6, follow-ups at 1/3/6 months after discharge; HP, hospital physician; ED, emergency department; GP,
general practitioner
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accepted in Swiss hospitals of different provenance and
if it has the potential to become a best clinical practice
model for hospital discharge and medication manage-
ment in the future [50].
Trial status
Patient recruitment has not yet started at the time of the
first submission in September 2018 and is planned to
start in early 2019 and last until mid-2019.
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